Ranluspec (ranibizumab biosimilar) / Lupin - LARVOL DELTA

Sandoz confirms European Commission approval for Ranluspec (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology (Sandoz Press Release) - "Ranluspec is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization...The approval paves the way for an expected launch of Ranluspec in the second half of 2026."

EMA approval • Launch Europe • Diabetic Macular Edema • Diabetic Retinopathy • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

...new medicines recommended for approval (European Medicines Agency) - "Ranluspec (ranibizumab), for the treatment of neovascular age-related macular degeneration, visual impairment and other retinopathies."

CHMP • Diabetic Macular Edema • Diabetic Retinopathy • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD (clinicaltrials.gov) - P3 | N=600 | Completed | Sponsor: Lupin Ltd. | Recruiting ➔ Completed | Trial completion date: Oct 2022 ➔ May 2024 | Trial primary completion date: Oct 2022 ➔ May 2024

Trial completion • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration